• Home>
  • Stocks>
  • Alembic Pharmaceuticals Ltd Share Price
Alembic Pharmaceuticals Ltd share price logo

Alembic Pharmaceuticals Ltd Share Price

NSE: APLLTD

BSE: 533573

Small Cap

Healthcare Sector

₹978.10

+7.00

(+0.72%)

as on

bell
The current prices are delayed by 15 mins, login to check live prices.

Tech Chart

Alembic Pharmaceuticals Ltd Stock Performance

as on September 17, 2025 at 4:01 pm IST

  • Day's Low

    Day's High

    ₹963
    ₹984.8
    downward going graph

    1.54%

    Downside

    0.69%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    ₹725.2
    ₹1,303.9
    downward going graph

    25.86%

    Downside

    33.31%

    Upside

    downward going graph

Alembic Pharmaceuticals Ltd share price movements today

Previous Close
₹971.10
Open
₹967.00
Volume
1.07L
Upper Circuit
₹1,165.30
Lower Circuit
₹776.90
Day's Low - High
₹963 - ₹984.8
52 Week Low - High
₹725.2 - ₹1,303.9

Alembic Pharmaceuticals Ltd Historical Returns

1 Month Return
-0.06 %
3 Month Return
+ 0.2 %
1 Year Return
-19.08 %
3 Year Return
+ 60.49 %
5 Year Return
-0.21 %

Alembic Pharmaceuticals Ltd Fundamentals

as on September 17, 2025 at 4:01 pm IST

Market Cap

₹19,088.24 Cr

Return on Equity (ROE)

9.96

PE Ratio (TTM)

31.7

Return on capital employed (ROCE)

11.4

Industry PE ratio

42.14

Beta (LTM)

0.48

P/B Ratio

3.52

Dividend Yield

1.18

PEG Ratio

-21.72

Quarterly Earnings Growth YOY

14.19

EPS (TTM)

29.61

Sector

Pharmaceuticals

Book Value

264.1

Technical Analysis

Bullish

View Technical Analysis

Alembic Pharmaceuticals Ltd Stock Valuation

as on September 17, 2025 at 4:01 pm IST

Alembic Pharmaceuticals Ltd in the last 5 years

  • Overview

  • Trends

Lowest (11.53x)

March 23, 2020

Today (31.70x)

September 16, 2025

Industry (42.14x)

September 16, 2025

Highest (53.41x)

January 3, 2023

LowHigh

Today’s Price to Earnings Ratio: 31.70x

Alembic Pharmaceuticals Ltd vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Alembic Pharmaceuticals Ltd with its industry peers.

Company
Analyst View
Market Cap(in ₹ Cr)
5 Year CAGRDebt to Asset Ratio
Net Profit(in ₹ Cr)
Yearly Revenue(in ₹ Cr)
Alembic Pharmaceuticals Ltd image
Alembic Pharmaceuticals Ltd
BUY19,088.24-0.04%0.615826,672
Sanofi India Ltd image
Sanofi India Ltd
BUY11,572.58-8.47%0.524132,013
Aurobindo Pharma Ltd image
Aurobindo Pharma Ltd
BUY63,961.066.93%0.603,48331,723
Zydus Lifesciences Ltd image
Zydus Lifesciences Ltd
HOLD1,04,094.9132.55%0.614,61423,241
Abbott India Ltd image
Abbott India Ltd
BUY65,726.2517.62%0.001,4146,445
See all

Analyst Recommendation on Alembic Pharmaceuticals Ltd Stock

Based on 11 analysts

BUY

63.64%

Buy

36.36%

Hold

0.00%

Sell

Based on 11 analysts, 63.64% of analysts recommend a 'BUY' rating for Alembic Pharmaceuticals Ltd. Average target price of ₹1056.64

Source: S&P Global Market Intelligence

Alembic Pharmaceuticals Ltd Share Price Target

Get share price movements and forecasts by analysts on Alembic Pharmaceuticals Ltd.

What analysts predicted

8.81%UPSIDE

Target Price

₹1056.64

Current Price

₹978.1

Analyzed by

11 Analysts

High

₹1275

Target

₹1056.64

Low

₹900

Alembic Pharmaceuticals Ltd target price ₹1056.64, a slight upside of 8.81% compared to current price of ₹978.1. According to 11 analysts rating.

Source: S&P Global Market Intelligence

Alembic Pharmaceuticals Ltd Stock's Interest Amongst Investors

Search interest for Alembic Pharmaceuticals Ltd Stock has increased by 17% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:17% versus previous 30 day period

Alembic Pharmaceuticals Ltd Quarterly Profit & Loss

Figures in Rupees Crores

Sep 2022
Dec 2022
Mar 2023
Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sales
1,475.01
1,509.02
1,406.45
1,486.15
1,594.93
1,630.57
1,516.98
1,561.73
1,647.98
1,692.74
1,769.64
1,710.72
Other Income
0.33
0.44
0.89
11.67
10.15
2.89
3.6
2.42
30.47
9.86
14.19
6.5
Total Income
1,475.34
1,509.46
1,407.34
1,497.82
1,605.08
1,633.46
1,520.58
1,564.15
1,678.45
1,702.6
1,783.83
1,717.22
Expenses
1,243.92
1,273.86
1,202.68
1,287.49
1,387.19
1,364.25
1,257.31
1,324.9
1,408.71
1,432.52
1,498.38
1,429.82
Operating Profit
231.09
235.16
203.77
198.66
207.74
266.32
259.67
236.83
239.27
260.22
271.26
280.9
Operating Profit Margin %
15.67%
15.58%
14.49%
13.37%
13.03%
16.33%
17.12%
15.16%
14.52%
15.37%
15.33%
16.42%
Profit Before Interest, Tax and Depreciation
231.42
235.6
204.66
210.33
217.89
269.21
263.27
239.25
269.74
270.08
285.45
287.4
Interest
12.41
14.6
14.37
14.39
15.69
15.17
10.94
13.18
18.81
22.26
24.52
23.52
Depreciation
67.7
66.51
74.12
66.18
67.56
69.45
69.48
69.04
70.51
70.04
68.99
73.77
Profit Before Tax
151.31
154.49
116.17
129.76
134.64
184.59
182.85
157.03
180.42
177.78
191.94
190.11
Tax Paid
17.96
32.57
-36.43
9.16
-1.92
4.14
4.64
22.49
27.28
40.08
35.31
36.48
Profit After Tax
133.35
121.92
152.6
120.6
136.56
180.45
178.21
134.54
153.14
137.7
156.63
153.63
Total Net profit including share of profit / Loss from associate company
133.35
121.92
152.6
120.6
136.56
180.45
178.21
134.54
153.14
137.7
156.63
153.63
EPS
6.78
6.2
7.76
6.14
6.95
9.23
9.07
6.84
7.79
7.01
7.98
7.85
Actual EPS
6.78
6.2
7.76
6.14
6.95
9.23
9.07
6.84
7.79
7.01
7.98
7.85
Adjusted EPS
6.78
6.2
7.76
6.14
6.95
9.23
9.07
6.84
7.79
7.01
7.98
7.85
Diluted EPS
6.78
6.2
7.76
6.14
6.95
9.23
9.07
6.84
7.79
7.01
7.98
7.85

Alembic Pharmaceuticals Ltd Annual Profit & Loss

Figures in Rupees Crores

Mar 2017
Mar 2018
Mar 2019
Mar 2020
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Sales
3,134.61
3,130.81
3,934.68
4,605.75
5,393.13
5,305.79
5,652.62
6,228.63
6,672.08
Other Income
2.02
7.03
9.38
40.36
87.29
55.74
2.74
28.31
56.29
Total Income
3,136.63
3,137.84
3,944.06
4,646.11
5,480.42
5,361.53
5,655.36
6,256.94
6,728.37
Expenses
2,519.34
2,487.72
3,061.1
3,461.8
3,912.85
4,431.63
4,975.17
5,296.25
5,663.84
Operating Profit
615.27
643.09
873.58
1,143.95
1,480.28
874.16
677.45
932.38
1,008.24
Operating Profit Margin %
19.63%
20.54%
22.2%
24.84%
27.45%
16.48%
11.98%
14.97%
15.11%
Profit Before Interest, Tax and Depreciation
617.29
650.12
882.96
1,184.31
1,567.57
929.9
680.19
960.69
1,064.53
Interest
5.23
3.4
18.41
27.16
16.02
17.73
50.17
56.19
78.77
Depreciation
82.97
105.46
115.23
157.32
183.47
286.78
275.43
272.67
278.58
Profit Before Tax
529.09
541.26
749.32
999.83
1,368.08
625.39
354.59
631.83
707.18
Tax Paid
122.19
120.35
156.75
199.18
253.32
104.45
12.6
16.01
125.17
Profit After Tax
406.9
420.91
592.57
800.65
1,114.76
520.94
341.99
615.82
582.01
Total Net profit including share of profit / Loss from associate company
403.07
412.82
583.29
800.7
1,146.5
520.94
341.99
615.82
582.01
EPS
21.39
21.89
31
43.97
60.81
26.5
17.4
31.33
29.68
Actual EPS
21.39
21.89
31
43.97
60.81
26.5
17.4
31.33
29.68
Adjusted EPS
21.39
21.89
31
43.97
60.81
26.5
17.4
31.33
29.68
Diluted EPS
21.39
21.89
31
43.97
60.81
26.5
17.4
31.33
29.68

Alembic Pharmaceuticals Ltd Cash Flow

Figures in Rupees Crores

Mar 2016
Mar 2017
Mar 2018
Mar 2019
Mar 2020
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Net Cash from Operating Activities
947.66
328.55
312.42
811.96
449.13
1,463.39
552.35
723.95
803.2
87.95
Cash Flow from Investing Activities
-5.7
-485.91
-884.38
-755.67
-731.22
-839.74
-371.97
-447.6
-320.6
-568.41
Cash Flow from Financing Activities
-224.3
-128.88
502.63
59.04
154.86
-597.43
-217.35
-261.96
-437.87
443.73
Net Cash Flow
416.55
-286.24
-69.33
115.33
-127.23
26.22
-36.97
14.39
44.73
-36.73

Alembic Pharmaceuticals Ltd Stock Shareholding Pattern

Numbers in percentages

Dec 2022
Mar 2023
Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Promoters
69.61%
69.61%
69.61%
69.61%
69.61%
69.61%
69.61%
69.61%
69.61%
69.67%
69.67%
DII
12.76%
13.31%
13.4%
13.93%
14.5%
15.38%
15.47%
16.05%
16.06%
16.43%
16.46%
FII
0%
0%
0%
0%
4.52%
4.46%
4.32%
3.94%
4.17%
3.94%
3.96%
Public
12.65%
12.53%
12.4%
11.67%
11.37%
10.54%
10.6%
10.39%
10.16%
9.96%
9.9%
Total Outstanding Shares
19,65,63,124
19,65,63,124
19,65,63,124
19,65,63,124
19,65,63,124
19,65,63,124
19,65,63,124
19,65,63,124
19,65,63,124
19,65,63,124
19,65,63,124
Total Shareholders
1,01,864
99,522
97,607
89,552
85,212
76,567
74,829
91,429
93,944
91,336
89,013

Mutual Funds that own Alembic Pharmaceuticals Ltd Stock

Check out the Mutual Funds with significant holdings in Alembic Pharmaceuticals Ltd.

Alembic Pharmaceuticals Ltd Earnings and Dividends

View detailed summary of the earnings and dividend history of Alembic Pharmaceuticals Ltd.

  • Alembic Pharmaceuticals Ltd Earnings Results

    Alembic Pharmaceuticals Ltd’s net profit jumped 14.6% since last year same period to ₹154.38Cr in the Q1 2025-2026. On a quarterly growth basis, Alembic Pharmaceuticals Ltd has generated -1.6% fall in its net profits since last 3-months.

    Read More about Earnings Results

  • Alembic Pharmaceuticals Ltd Dividends May,2025

    In the quarter ending March 2025, Alembic Pharmaceuticals Ltd has declared dividend of ₹11.00 per share on 06 May 2025 - translating a dividend yield of 2.27%.

    Read More about Dividends

Indices Featuring Alembic Pharmaceuticals Ltd Stock

Check stock indices that include Alembic Pharmaceuticals Ltd.

BSE Healthcare

₹44,738.73

-0.08 (▲-37.44%)

S&P BSE 250 SmallCap

₹6,988.54

0.46 (▲32.27%)

Nifty Smallcap 250

₹17,470.75

0.51 (▲88.55%)

Nifty MidSmallcap 400

₹20,277.15

0.3 (▲60.35%)

BSE 500

₹36,813.13

0.32 (▲115.74%)

Nifty 500

₹23,445.20

0.32 (▲75.9%)

S&P BSE 400 MidSmallCap

₹12,291.60

0.29 (▲35.8%)

BSE Small-Cap

₹54,537.03

0.51 (▲276.99%)

Insights on Alembic Pharmaceuticals Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Promoter Holding Up

    img

    Promoters have increased holdings from 69.67% to 69.68% in Jun 2025 quarter

  • imgPOSITIVE IMPACT

    FII Holding Up

    img

    Foreign Institutions have increased holdings from 3.94% to 3.96% in Jun 2025 quarter

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 7 days, APLLTD stock has moved up by 2.0%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Torrent Pharmaceuticals Ltd has given 138.8% return, outperforming this stock by 78.3%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Divis Laboratories Ltd has given 11.9% return, outperforming this stock by 31.0%

  • imgNEGATIVE IMPACT

    MF Holding Down

    img

    Mutual Funds have decreased holdings from 9.20% to 9.05% in Jun 2025 quarter

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 2 quarters, 1.78K Cr → 1.71K Cr (in ₹), with an average decrease of 3.7% per quarter

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, 156.89 Cr → 154.38 Cr (in ₹), with an average decrease of 1.6% per quarter

  • imgNEGATIVE IMPACT

    Retail Holding Down

    img

    Retail Investor have decreased holdings from 9.96% to 9.90% in Jun 2025 quarter

About Alembic Pharmaceuticals Ltd

Alembic Pharmaceuticals is a leading generic pharmaceuticals manufacturer and marketer based in India. Established in 2010 as a subsidiary of Alembic Ltd., they stopped being a subsidiary in 2011 when they were allotted 133515914 equity shares of Rs 2 each to their shareholders. In 2014 Alembic Pharmaceuticals entered into a joint venture with Adwiya Mami SARL, Algeria and in 2015 an exclusive agreement was signed with Novartis. In 2016, Alembic Pharmaceuticals formed Aleor Dermaceuitical Limited in a 60:40 joint venture with Orbicular and a state-of-the-art anticancer manufacturing facility opened in Gujarat in 2017. One year later Alembic Pharmaceuticals completed the acquisition of Orit Laboratories LLC, a generic drug developer, along with real estate. In 2018 Alembic Pharmaceuticals was inspected by the US FDA and were issued with 3 observations. In 2019, they launched 9 new products in the US, and the novel Umbralicib UKONIQ was licensed by TG Therapeutics USA in 2021. In 2022, Aleor Dermaceuticals was amalgamated into Alembic Pharmaceutical and became a wholly owned subsidiary.

Revenue: ₹1,710.72Cr as on June 2025 (Q1 FY26)
Net Profit: ₹153.63Cr as on June 2025 (Q1 FY26)
Listing date: 20 Sep, 2011
Chairperson Name: Chirayu R Amin
OrganisationAlembic Pharmaceuticals Ltd
HeadquartersVadodara
IndustryPharmaceuticals
CEOChirayu R Amin
E-voting on sharesClick here to vote

FAQs

What is Alembic Pharmaceuticals Ltd share price today?

Alembic Pharmaceuticals Ltd share price today stands at ₹978.1 as on at the close of the market. Alembic Pharmaceuticals Ltd share today touched a day high of ₹984.8 and a low of ₹963.

What is the 52 week high and 52 week low range for Alembic Pharmaceuticals Ltd share?

Alembic Pharmaceuticals Ltd touched a 52 week high of ₹1303.9 and a 52 week low of ₹725.2. Alembic Pharmaceuticals Ltd share price today i.e. is closed at ₹978.1, which is -24.99% down from its 52 week high and 34.87% up from its 52 week low.

What is Alembic Pharmaceuticals Ltd's market capitalisation today?

Alembic Pharmaceuticals Ltd market capitalisation is ₹19,088.24 Cr as on .

How to buy Alembic Pharmaceuticals Ltd shares?

To buy Alembic Pharmaceuticals Ltd shares, you need to follow these steps:

  • Open a Demat account and Trading account on INDmoney
  • Fund your Trading account
  • Search for APLLTD or Alembic Pharmaceuticals Ltd on the INDmoney app to check live prices of the stock
  • Click on Buy or SIP to place an order to invest in Alembic Pharmaceuticals Ltd shares. You can invest by selecting the number of shares or set up a fixed SIP to invest every month or week.

What is Alembic Pharmaceuticals Ltd trading volume today?

Alembic Pharmaceuticals Ltd trading volume is 1.07L as on . This means that 1.07L shares of Alembic Pharmaceuticals Ltd were bought and sold on the stock market during today's trading session.